Fig. 5.

Clinical course Three

weeks after the initial visit, methylprednisolone (mPSL) pulse therapy (1g/day × 3) was initiated, followed by rituximab (0.5g/week × 4) administration. Three months after the treatment, when serous retinal detachment (SRD) appeared in the macular area, prednisolone (PSL) dose was increased along with the administration of oral azathioprine and subtenon triamcinolone acetonide (STTA) (40mg). In response to these treatments, SRD disappeared, and the remission has been maintained to date.